Preclinical studies have shown that tumour-selective alpha-folate-targeted inhibitors only display flares in tumours, compared to TS inhibitors that target both the reduced folate carrier (RFC) and alpha folate transporters [14]. This evidence concerns the gene TYMS and neoplasm.